PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32828276-0	2020	Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.	cercosporamide	50-64	eukaryotic translation initiation factor 4E	Homo sapiens	30-35	
29212818-7	2018	Treatment of NPCs with the cercosporamide, a MAPK-interacting kinases inhibitor, reduced eIF4E phosphorylation and KDM5A protein expression, increased GFAP levels, and enhanced astrocytogenesis.	cercosporamide	27-41	eukaryotic translation initiation factor 4E	Homo sapiens	89-94	
27662474-0	2016	Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.	cercosporamide	65-79	eukaryotic translation initiation factor 4E	Homo sapiens	14-45	
27662474-6	2016	Cercosporamide blocked the phosphorylation of eIF4E but not Erk or p38 in a dose- and time-dependent manner in HCC and HCC-EC cells, suggesting that suppression of eIF4E phosphorylation was the result of inhibition of Mnk but not Mnk upstream pathways.	cercosporamide	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	46-51	
27662474-6	2016	Cercosporamide blocked the phosphorylation of eIF4E but not Erk or p38 in a dose- and time-dependent manner in HCC and HCC-EC cells, suggesting that suppression of eIF4E phosphorylation was the result of inhibition of Mnk but not Mnk upstream pathways.	cercosporamide	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	164-169	
27662474-7	2016	Overexpression of constitutively active eIF4E (S209D) but not the nonphosphorylatable eIF4E (S209A) abolished the inhibitory effects of cercosporamide in HepG2 cells.	cercosporamide	136-150	eukaryotic translation initiation factor 4E	Homo sapiens	40-45	
27662474-8	2016	Altogether, our work demonstrates that cercosporamide acts as a Mnk inhibitor through blockage of eIF4E phosphorylation and selectively exhibits anti-HCC activities.	cercosporamide	39-53	eukaryotic translation initiation factor 4E	Homo sapiens	98-103	
23509154-4	2013	Treatment of AML cells with cercosporamide resulted in a dose-dependent suppression of eIF4E phosphorylation.	cercosporamide	28-42	eukaryotic translation initiation factor 4E	Homo sapiens	87-92	
23509154-5	2013	Such suppression of Mnk kinase activity and eIF4E phosphorylation by cercosporamide resulted in dose-dependent suppressive effects on primitive leukemic progenitors (CFU-L) from AML patients and enhanced the antileukemic properties of cytarabine (Ara-C) or mammalian target of rapamycin (mTOR) complex 1 inhibition.	cercosporamide	69-83	eukaryotic translation initiation factor 4E	Homo sapiens	44-49	
23509154-7	2013	Altogether, this work demonstrates that the unique Mnk inhibitor cercosporamide suppresses phosphorylation of eIF4E and exhibits antileukemic effects, in support of future clinical-translational efforts involving combinations of Mnk inhibitors with cytarabine and/or mTOR inhibitors for the treatment of AML.	cercosporamide	65-79	eukaryotic translation initiation factor 4E	Homo sapiens	110-115